# Effectiveness of Drug Eluting TACE in Primary HCC

> **NCT04048317** · EARLY_PHASE1 · UNKNOWN · sponsor: **Assiut University** · enrollment: 75 (estimated)

## Conditions studied

- Hepatic Cell Carcinoma

## Interventions

- **DRUG:** HepaSphere Microspheres/Doxorubicin Hydrochloride
- **DRUG:** Lipiodol

## Key facts

- **NCT ID:** NCT04048317
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04048317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04048317, "Effectiveness of Drug Eluting TACE in Primary HCC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04048317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*